Insulin Lispro Injection, an authorized generic version of Humalog U-100, has been made available by Lilly at a 50% lower list price.
The authorized generic product may be substituted for the brand as it contains the same molecule as Humalog, a rapid-acting insulin indicated to improve glycemic control in adults and children with diabetes mellitus.
Insulin Lispro 100 Units/mL will be supplied in single vials ($137.35) or 5-count KwikPens ($265.20). Humalog will still be available for patients who wish to continue using the brand product. For patients with insurance, pharmacists will be able to provide information on which option provides the most savings.
“Lilly will continue to work with health plans, wholesalers, employers and the government to work toward permanent solutions that will help every person with diabetes afford their medicines,” said Mike Mason, senior vice president, Connected Care and Insulins.
For more information visit lilly.com.
This article originally appeared on MPR